A Randomised Dose De-Escalation Study of Oral Fludarabine, ±Oral Cyclophosphamide and Intravenous Rituximab As First-Line Therapy of Fit Patients with Chronic Lymphocytic Leukaemia (CLL) Aged ≥65 Years: Final Analysis of Response and Toxicity
Stephen P. Mulligan(Royal North Shore Hospital), Bryone J. Kuss(Flinders Medical Centre), Paul Turner(University of Oxford), Rosemary Harrup(University of Tasmania), Juliana Di Iulio(Peter MacCallum Cancer Centre), Maya Latimer(Georgetown University), Devinder Gill(Princess Alexandra Hospital), Gavin Cull(Sir Charles Gairdner Hospital), William Renwick(The Royal Melbourne Hospital), Mathias Bressel(Peter MacCallum Cancer Centre), Naomi Mackinlay(Royal North Shore Hospital), Melanie Sulda(Flinders Medical Centre), Cecily Forsyth(Gosford Hospital), Leanne Berkahn(Auckland City Hospital), Philip Campbell(Barwon Health), David Simpson(North Shore Hospital), Giles Best(Flinders University)
Cited by 21
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.6k
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
|American Journal of Hematology|2019|472
Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
|The Lancet|2021|456
Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma
|New England Journal of Medicine|2018|429